Terapias innovadoras para el tratamiento de las distrofias hereditarias de la retina | Janssen

Skip to main content

Página principal
Distrofias hereditarias de la retina
Beneficios del diagnóstico genético
Consideraciones para el diagnóstico genético
Avances científicos
Recursos adicionales

Volver al principio

1. Bakall B, et al. Ophthalmic Surg Lasers Imaging Retina 2018; 49(7):472–478.
2. European Commission. Union Register of medicinal products for human use. 2021. Disponible en: https://ec.europa.eu/health/documents/community-register/html/h1331.htm (Último acceso Mayo 2023).
3. National Institute for Health and Care Excellence (NICE). Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations. 2019. Disponible en: https://www.nice.org.uk/guidance/hst11/chapter/1-Recommendations (Último acceso mayo 2023).
4. Ficha técnica de Luxturna®. Disponible en: https://www.ema.europa.eu/documents/product-information/luxturna-epar-product-information_en.pdf (Último acceso Mayo 2023).
5. ClinicalTrials.gov. Inherited retinal disease. Disponible en: https://clinicaltrials.gov/ct2/results?term=gene+therapy&cond=inherited+retinal+disease&Search=Apply&recrs=b&recrs=a&recrs=f&recrs=d&age_v=&gndr=&typ%E2%80%A6 (Último acceso Mayo 2023).
6. ClinicalTrials.gov. Gene therapy for achromatopsia (CNGA3) [NCT03758404]. 2021. Disponible en: https://clinicaltrials.gov/ct2/show/NCT03758404?recrs=e&cond=Achromatopsia&draw=2 (Último acceso Mayo 2023).
7. ClinicalTrials.gov. Stargardt disease. Disponible en: https://clinicaltrials.gov/ct2/results?recrs=&cond=Stargardt+Disease&term=&cntry=&state=&city=&dist= (Último acceso Mayo 2023).
8. Vázquez-Domínguez I, et al. Genes 2019; 10(9):654–684.
9. Lee JH, et al. Prog Retin Eye Res 2019; 68:31–53.
10. Branham K, et al. Am J Med Genet C Semin Med Genet 2020; 184(3):571–577.
11. RetNet. Summaries of genes and loci causing retinal diseases: mapped and identiﬁed retinal disease genes. 2021. Disponible en: https://web.sph.uth.edu/RetNet/sum-dis.htm (Último acceso Mayo 2023).
12. Lam BL, et al. Orphanet J Rare Dis 2021 Dec 14; 16(1):514.
13. Lee KY, Garg S. Genet Med 2015; 17(4):245–252.
14. Moore AT. Ophthalmology 2017; 124(9):1254–1255.
15. ClinicalTrials.gov. Clinical trial of gene therapy for the treatment of Leber congenital amaurosis (LCA) (OPTIRPE65) [NCT02781480]. 2021. Disponible en: https://clinicaltrials.gov/ct2/show/NCT05513053?rank=1 (Último acceso Mayo 2023).
16. ClinicalTrials.gov. Inherited retinal dystrophy. Disponible en: https://clinicaltrials.gov/ct2/results?cond=INHERITED+RETINAL+DYSTROPHY&Search=Apply&recrs=a&recrs=f&recrs=d&age_v=&gndr=&type=&rslt= (Último acceso Mayo 2023).
17. Fry LE, et al. Int J Mol Sci 2020; 21(3):777.
18. A study to evaluate the safety and tolerability of QR-1123 in subjects with autosomal dominant retinitis pigmentosa due to the P23H mutation in the RHO gene (Aurora). Disponible en: https://clinicaltrials.gov/ct2/show/NCT04123626 (Último acceso Mayo 2023).
19. Russell SR, et al. Intravitreal antisense oligonucleotide sepofarsen in Leber congenital amaurosis type 10: a phase 1b/2 trial. Nat Med. 2022 May;28(5):1014-1021.
20. Sahel JA, et al. Nat Med. 2021 Jul;27(7):1223-1229.
21. Prem Senthil M, et al. J Patient Rep Outcomes 2017; 1(1):15.
22. Lam BL, et al. Orphanet J Rare Dis 2021 Dec 14; 16(1):514.